How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

22 results for

Recombinant Staphylokinase

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS

Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2017 Clinical Trials

2. Recombinant Staphylokinase

Recombinant Staphylokinase Recombinant Staphylokinase Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Recombinant Staphylokinase (...) Recombinant Staphylokinase Aka: Recombinant Staphylokinase From Related Chapters II. Advantages More fibrin specific then Less likely to cause bleeding complications May yield better patency if given at twice dose III. Disadvantages Biological product generates immune response May only be able to give once IV. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Recombinant Staphylokinase." Click on the image (or right click

2018 FP Notebook

3. Single Bolus Recombinant Nonimmunogenic Staphylokinase (FORtelyzin) Versus Single Bolus Tenecteplase (Metalyse) in STEMI

Single Bolus Recombinant Nonimmunogenic Staphylokinase (FORtelyzin) Versus Single Bolus Tenecteplase (Metalyse) in STEMI Single Bolus Recombinant Nonimmunogenic Staphylokinase (FORtelyzin) Versus Single Bolus Tenecteplase (Metalyse) in STEMI - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Single Bolus Recombinant Nonimmunogenic Staphylokinase (FORtelyzin) Versus Single Bolus Tenecteplase (Metalyse) in STEMI (FORMAT-1) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02301910 Recruitment Status : Unknown

2014 Clinical Trials

4. The pharmaceutics from the foreign empire: the molecular pharming of the prokaryotic staphylokinase in Arabidopsis thaliana plants (PubMed)

The pharmaceutics from the foreign empire: the molecular pharming of the prokaryotic staphylokinase in Arabidopsis thaliana plants Here, we present the application of microbiology and biotechnology for the production of recombinant pharmaceutical proteins in plant cells. To the best of our knowledge and belief it is one of few examples of the expression of the prokaryotic staphylokinase (SAK) in the eukaryotic system. Despite the tremendous progress made in the plant biotechnology, most (...) of the heterologous proteins still accumulate to low concentrations in plant tissues. Therefore, the composition of expression cassettes to assure economically feasible level of protein production in plants remains crucial. The aim of our research was obtaining a high concentration of the bacterial anticoagulant factor-staphylokinase, in Arabidopsis thaliana seeds. The coding sequence of staphylokinase was placed under control of the β-phaseolin promoter and cloned between the signal sequence of the seed storage

Full Text available with Trip Pro

2016 World journal of microbiology & biotechnology

5. Expression of recombinant staphylokinase in the methylotrophic yeast Hansenula polymorpha (PubMed)

Expression of recombinant staphylokinase in the methylotrophic yeast Hansenula polymorpha Currently, the two most commonly used fibrinolytic agents in thrombolytic therapy are recombinant tissue plasminogen activator (rt-PA) and streptokinase (SK). Whereas SK has the advantage of substantially lower costs when compared to other agents, it is less effective than either rt-PA or related variants, has significant allergenic potential, lacks fibrin selectivity and causes transient hypotensive (...) effects in high dosing schedules. Therefore, development of an alternative fibrinolytic agent having superior efficacy to SK, approaching that of rt-PA, together with a similar or enhanced safety profile and advantageous cost-benefit ratio, would be of substantial importance. Pre-clinical data suggest that the novel fibrinolytic recombinant staphylokinase (rSAK), or related rSAK variants, could be candidates for such development. However, since an efficient expression system for rSAK is still lacking

Full Text available with Trip Pro

2012 BMC biotechnology

6. Recombinant Staphylokinase

Recombinant Staphylokinase Recombinant Staphylokinase Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Recombinant Staphylokinase (...) Recombinant Staphylokinase Aka: Recombinant Staphylokinase From Related Chapters II. Advantages More fibrin specific then Less likely to cause bleeding complications May yield better patency if given at twice dose III. Disadvantages Biological product generates immune response May only be able to give once IV. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Recombinant Staphylokinase." Click on the image (or right click

2015 FP Notebook

7. Effectiveness and Safety of Thrombolytics for the Treatment of Ischemic Stroke

Appendix 4: Supplementary Analyses 22 References 24 Effectiveness and Safety of Thrombolytics for Ischemic Stroke: A Rapid Review. January 2013; pp. 1–25. 5 List of Abbreviations CI confidence interval(s) HQO Health Quality Ontario OR odds ratio OHTAC Ontario Health Technology Advisory Committee RCT randomized controlled trial rt-PA Recombinant tissue plasminogen activator Effectiveness and Safety of Thrombolytics for Ischemic Stroke: A Rapid Review. January 2013; pp. 1–25. 6 Background Objective (...) . (2) Intravenous administration of the recombinant tissue plasminogen activator (rt-PA) was the first Health Canada approved pharmaceutical thrombolytic treatment for ischemic stroke. (2) Originally, rt-PA was approved for administration within 3 hours of onset of stroke. However, the Canadian Stroke Network has recently referenced research that suggests this may be extended to up to 4.5 hours. (2) The Canadian Stroke Network also recommends that best practice includes the administration of rt-PA

2013 Health Quality Ontario

8. Optimized Timing of Thrombolytic Therapy for the Treatment of Stroke

. January 2013; pp. 1–21. 5 List of Abbreviations CI Confidence interval(s) HQO Health Quality Ontario MRS Modified Rankin score OR Odds ratio OHTAC Ontario Health Technology Advisory Committee RCT Randomized controlled trial RT-PA Recombinant tissue plasminogen activator SICH Symptomatic intracranial hemorrhage Optimized Timing of Thrombolytics for Stroke: A Rapid Review. January 2013; pp. 1–21. 6 Background Objective of Analysis The objective of this analysis is to determine the optimal timing (...) such pharmaceutical agents, including streptokinase, urokinase, and recombinant tissue plasminogen activator (rt-PA). Currently, intravenous rt- PA is approved by Health Canada for use in adults with acute ischemic stroke within three hours of symptom onset. (2) Clinical trials and subsequent meta-analyses highlight a fine balance between the positive functional outcomes with rt-PA and the risk of serious adverse effects, especially symptomatic intracranial hemorrhage (SICH), which is associated with the decline

2013 Health Quality Ontario

9. Molecular Interactions of Human Plasminogen with Fibronectin-binding Protein B (FnBPB), a Fibrinogen/Fibronectin-binding Protein from Staphylococcus aureus (PubMed)

Molecular Interactions of Human Plasminogen with Fibronectin-binding Protein B (FnBPB), a Fibrinogen/Fibronectin-binding Protein from Staphylococcus aureus Staphylococcus aureus is a commensal bacterium that has the ability to cause superficial and deep-seated infections. Like several other invasive pathogens, S. aureus can capture plasminogen from the human host where it can be converted to plasmin by host plasminogen activators or by endogenously expressed staphylokinase. This study (...) demonstrates that sortase-anchored cell wall-associated proteins are responsible for capturing the bulk of bound plasminogen. Two cell wall-associated proteins, the fibrinogen- and fibronectin-binding proteins A and B, were found to bind plasminogen, and one of them, FnBPB, was studied in detail. Plasminogen captured on the surface of S. aureus- or Lactococcus lactis-expressing FnBPB could be activated to the potent serine protease plasmin by staphylokinase and tissue plasminogen activator. Plasminogen

Full Text available with Trip Pro

2016 The Journal of biological chemistry

10. Jetrea - ocriplasmin

greatest 48 h after injection and were cleared 7 days after injection. Assessment Report EMA/CHMP/74766/2013 Page 22/91 Other toxicity studies Immunogenicity Non-human product-related impurities related to P. pastoris host cell proteins and staphylokinase have the potential to cause immunogenicity. A study was performed using batch of ocriplasmin not used in the pivotal non-clinical studies, or during clinical development to assess immunogenicity of host cell protein content at the time. Immunogenicity (...) . Ecotoxicity/environmental risk assessment The applicant provided a suitable justification for not performing an Environmental Risk Assessment (ERA) in line with the guidance from the “Guideline on the Environmental Risk Assessment of the medicinal products for human use” (EMEA/CHMP/SWP/4447/00). Ocriplasmin is a recombinant protein and is unlikely to result in significant risk to the environment. No further evaluation of ocriplasmin has been provided and this was considered acceptable. 2.2.10. Discussion

2013 European Medicines Agency - EPARs

11. Thrombolysis, Peripheral

is not being used for peripheral vascular work. Several other new thrombolytic agents are under review, but only recombinant human urokinase, recombinant glycosylated pro-urokinase, and recombinant staphylokinase have been used for peripheral arterial occlusion. Early data suggest that recombinant glycosylated pro-urokinase and recombinant staphylokinase may be effective without inducing fibrinogen depletion. This fibrinogen-conserving property may prove to be a tremendous advantage in lessening (...) Stroke Association (AHA/ASA) revised the guidelines for the administration of tPA following acute ischemic stroke, expanding the treatment window from 3 hours to 4.5 hours after symptom onset. This expansion of the recombinant tPA (r-tPA; alteplase) window has not yet been approved by the Food and Drug Administration, and it is emphasized that time is still of the utmost importance when treating stroke. [ ] Saver et al reported that treatment with tPA in the 3- to 4.5-hour window confers benefit

2014 eMedicine Radiology

12. Fibrinolytic agents for peripheral arterial occlusion. (PubMed)

. Recently drugs such as pro-urokinase, recombinant staphylokinase and alfimperase have been introduced. This is an update of a review first published in 2010.To determine which fibrinolytic agents are most effective in peripheral arterial ischaemia.For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched March 2013) and CENTRAL (2013, Issue 3) for randomised controlled trials (RCTs) comparing fibrinolytic agents (...) Fibrinolytic agents for peripheral arterial occlusion. Peripheral arterial thrombolysis is used in the management of peripheral arterial ischaemia. Streptokinase was originally used but safety concerns led to a search for other agents. Urokinase and recombinant tissue plasminogen activator (rt-PA) have increasingly become established as first line agents for peripheral arterial thrombolysis. Potential advantages of these agents include improved safety, greater efficacy and a more rapid response

Full Text available with Trip Pro

2013 Cochrane database of systematic reviews (Online)

13. A Trial Using Double-Bolus THR-100 Versus Streptokinase

Limited Study Details Study Description Go to Brief Summary: This novel fibrinolytic agent is a 136 amino acid single chain protein secreted by some strains of Staphylococcus aureus and readily produced by recombinant DNA technology. Two natural variants of recombinant staphylokinase, THR-100 and SakSTAR, have been developed for investigational use in preliminary trials. Like SK, it forms an equimolar complex with plasmin which in turn activates plasminogen to plasmin. Unlike SK, the complexed (...) Infarction Drug: THR-100 Drug: Streptokinase Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 120 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Prospective Phase III Parallel, Randomised Controlled Trial Using Double-bolus Recombinant Staphylokinase (THR-100) vs Streptokinase in Patients With Acute Myocardial Infarction Study

2010 Clinical Trials

14. Fibrinolytic agents for peripheral arterial occlusion. (PubMed)

. Recently drugs such as pro-urokinase, recombinant staphylokinase and alfimperase have been introduced.To determine which fibrinolytic agents are most effective in peripheral arterial ischaemia.The Cochrane Peripheral Vascular Diseases Group searched their Specialised Register (last searched October 2009) and the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (last searched 2009, Issue 4) for randomised controlled trials (RCTs) comparing fibrinolytic agents to treat (...) Fibrinolytic agents for peripheral arterial occlusion. Peripheral arterial thrombolysis is used in the management of peripheral arterial ischaemia. Streptokinase was originally used but safety concerns led to a search for other agents. Urokinase and recombinant tissue plasminogen activator (rt-PA) have increasingly become established as first line agents for peripheral arterial thrombolysis. Potential advantages of these agents include improved safety, greater efficacy and a more rapid response

Full Text available with Trip Pro

2010 Cochrane database of systematic reviews (Online)

15. Thorombolytic therapy with rescue percutaneous coronary intervention versus primary percutaneous coronary intervention in patients with acute myocardial infarction: a multicenter randomized clinical trial. (PubMed)

of this study.This multicenter, open-label, randomized, parallel trial was conducted in 12 hospitals on patients (age < or = 70 years) with STEMI who presented within 12 hours of symptom onset (mean interval > 3 hours). Patients were randomized to three groups: primary PCI group (n = 101); recombinant staphylokinase (r-Sak) group (n = 104); and recombinant tissue-type plasminogen activator (rt-PA) group (n = 106). For all patients allocated to the thrombolytic therapy arm, coronary angiography was performed

2010 Chinese medical journal

16. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator. (PubMed)

Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator. The fibrin-specificity and procoagulant effects of recombinant staphylokinase (Sak42D) were compared with those of recombinant tissue-type plasminogen activator (rt-PA) in patients with acute myocardial infarction. Plasma samples were obtained at baseline and at 25 and 90 min, from 24 patients who were randomly assigned to a double bolus (15 mg each, 30 min apart) administration of Sak42D

1996 Thrombosis and haemostasis

17. Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis. (PubMed)

to streptokinase for the dissolution of whole blood or plasma clots, but significantly more potent for the dissolution of platelet-rich or retracted thrombi. The feasibility of fibrin-specific coronary thrombolysis with an intravenous infusion over 30 min of 10 mg recombinant staphylokinase was demonstrated in two small pilot studies in patients with acute myocardial infarction with angiographically confirmed total occlusion of the infarct-related coronary artery. However, neutralizing antibodies against (...) staphylokinase were demonstrable from the third week on in all patients. Definition of the therapeutic benefit of recombinant staphylokinase will require more detailed dose-finding studies followed by randomized efficacy studies against other thrombolytic agents. An interim analysis after 50 patients of a randomized trial of recombinant tissue-type plasminogen activator versus staphylokinase in patients with acute myocardial infarction revealed similar rates of coronary patency at 90 minutes

1995 Verhandelingen - Koninklijke Academie voor Geneeskunde van België

18. Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). (PubMed)

Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). A fibrinolytic agent more effective than streptokinase available for bolus injection with reasonable cost-effectiveness is a desirable goal. Pilot studies with bolus pegulated staphylokinase (PEG-Sak) have revealed excellent Thrombolysis In Myocardial Infarction (TIMI) 3 60-minute flow.We evaluated patients with acute ST-elevation myocardial infarction within 6 hours of chest pain onset to determine a dose (...) of PEG-Sak that had at least equal efficacy to recombinant tissue plasminogen activator (rt-PA) while maintaining an acceptable safety profile. After the initial study of 38 patients, of whom 27 received PEG-Sak, enrollment was temporarily halted because 3 patients receiving PEG-Sak had intracranial hemorrhage: 1 at a dose of 0.15 mg/kg and 2 at a dose of 0.05 mg/kg. Overall, 378 patients were studied across a PEG-Sak dose range from 0.01 mg/kg to 0.015 mg/kg, and 122 patients received accelerated rt

2003 American heart journal

19. [A randomized multicenter trial comparing recombinant staphylokinase with recombinant tissue-type plasminogen activator in patients with acute myocardial infarction]. (PubMed)

[A randomized multicenter trial comparing recombinant staphylokinase with recombinant tissue-type plasminogen activator in patients with acute myocardial infarction]. The aim of the study was to compare the safety and clinical efficacy of recombinant staphylokinase (r-Sak) with recombinant tissue-type plasminogen activator (rt-PA) in patients with acute myocardial infarction (AMI).This multicenter, open-label, randomized, parallel trial was conducted in 12 hospitals from January 2002 to October

2007 Zhonghua xin xue guan bing za zhi

20. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. (PubMed)

A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. Recombinant staphylokinase (STAR) was shown recently to offer promise for coronary arterial thrombolysis in patients with evolving myocardial infarction. The present multicenter randomized open trial was designed to assess the thrombolytic efficacy, safety, and fibrin specificity of STAR relative to accelerated alteplase (recombinant tissue-type

1995 Circulation

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>